Mission Bio
Maker of the Tapestri single-cell DNA, RNA, and protein analysis platform for oncology and CRISPR labs.
On the record
Checkpoint: HCA 2026 general meeting where single-cell platform data and roadmaps get compared head to head
The call
Mission Bio holds real chemistry-based differentiation in single-cell multi-omics, but its funding disclosures have gone quiet just as a much larger rival eyes the same niche.
Mission Bio sells a machine called Tapestri that lets scientists study the genetics and proteins inside single cells, mainly for cancer research and checking if gene-editing experiments work. The company has real advantages because it built custom microfluidic technology (tiny channels that handle fluids precisely) and has customers locked into its system, but these advantages are not protected by patents or exclusive deals. 10x Genomics, which is ten to twenty times bigger and publicly traded, could fairly easily build a competing product and is already moving into the same market. The thing to watch is whether 10x actually releases a single-cell DNA tool on its existing Chromium machine. If that happens, Mission Bio's window to stay unique could close quickly, which is why the company's funding signals have been weak and its future looks uncertain.
Why
01
AI pressure: None apparent. No AI lab or agent directly threatens Mission Bio's wet-lab hardware and chemistry business today. Could AI do the core job? Unlikely.
02
Bigger players: 10x Genomics. 10x Genomics is far bigger and already moving into multi-omics, putting Mission Bio's DNA+protein niche within reach of its Chromium platform. Could a giant copy it? Yes, easily.
03
What protects it. Proprietary microfluidic chemistry reads DNA and protein together in single cells, and oncology/CRISPR labs are locked into that workflow.
What would change this call
10x Genomics announces or ships a DNA+RNA+protein product on Chromium within 12-18 months. Would show 10x directly copying Mission Bio's core technical differentiation.
Terms of Mission Bio's August 2025 Ally Bridge-led round become disclosed. Flat or down valuation would confirm runway pressure rather than growth momentum.
FDA or regulatory bodies designate Tapestri as a reference method for cell-therapy QC or MRD monitoring. Would create a regulatory barrier slowing 10x Genomics from fast-copying the niche.
Terms of Mission Bio's August 2025 Ally Bridge-led round become disclosed. Flat or down valuation would confirm runway pressure rather than growth momentum.
FDA or regulatory bodies designate Tapestri as a reference method for cell-therapy QC or MRD monitoring. Would create a regulatory barrier slowing 10x Genomics from fast-copying the niche.
Key numbers
- Series C raised $70M
- Series B raised $30M
- Aug 2025 financing round size undisclosed
Named risks
- August 2025 financing amount and valuation undisclosed, raising runway and dilution uncertainty.
- 10x Genomics, 10-20x larger and well-funded, could enter Mission Bio's DNA+protein niche with no structural barrier.
- No confirmed recent revenue or headcount figures; opacity limits verification of growth trajectory.
- Elevated biopharma sector layoffs and capex constraints through mid-2026 could suppress instrument sales.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| 10x Genomics | contesting | 10x is expanding into multi-omics/spatial, directly bordering Mission Bio's DNA+protein niche as of 2026-03-20 |
| Akoya Biosciences | contesting | Competes in adjacent spatial proteomics/multiplexed imaging space per peer comparisons |
| Illumina | contesting | Sequencing incumbent whose platforms underlie much single-cell workflow competition |
| Parse Biosciences | gaining on | Named as single-cell RNA-seq alternative in 2024-06-17 bioRxiv comparative analysis |
Questions people ask
- Is Mission Bio profitable in 2026?
- No public revenue or profit figures have been disclosed. Mission Bio raised an equity round led by Ally Bridge Group in August 2025 without disclosing the amount, suggesting the company is still private, venture-backed, and not confirmed profitable as of late 2025.
- Who owns Mission Bio?
- Mission Bio is privately held and venture-capital backed, with investors including Ally Bridge Group, Novo Holdings, Agilent Technologies, and Mayfield. Its most recent equity financing, led by Ally Bridge Group, closed August 5, 2025, with amount and valuation undisclosed.
- Could AI replace Mission Bio's business?
- Unlikely for its core business. Mission Bio's revenue comes from Tapestri hardware, consumables, and proprietary microfluidic chemistry for single-cell DNA and protein capture, which AI cannot replicate. Only its bioinformatics analysis software layer, like the Mosaic pipeline, is exposed to generic AI/software substitution.
- Is 10x Genomics Mission Bio's biggest competitor?
- Yes. 10x Genomics is roughly 10 to 20 times larger, publicly traded (NASDAQ: TXG, $46.29 on 2026-07-24), reported about $640 million in 2024 revenue, and is expanding into multi-omics territory that overlaps with Mission Bio's single-cell DNA plus protein niche.
- Who is Mission Bio's CEO?
- Brian Kim was appointed CEO of Mission Bio on January 4, 2024, per the company's own announcement, taking over leadership as the company pushed into expanded single-cell tri-omics (DNA, RNA, protein) product development.
- What does Mission Bio's Tapestri platform actually do?
- Tapestri is an instrument-plus-consumables-plus-software platform for simultaneous single-cell DNA, protein, and (as of 2025) RNA analysis, used in oncology, cell and gene therapy characterization, and CRISPR editing quality control, per the company's product page.
Timeline
- 2025-11-20Launched Single-Cell Targeted DNA + RNA Assay at ASH 2025
- 2025-10-09Appointed Dr. Zivjena Vucetic as Chief Medical Officer
- 2025-08-05Closed undisclosed equity financing led by Ally Bridge Group; named new CCO
- 2025-07-27Launched Single-Cell Targeted Genotype + Gene Expression assay (>10,000 cells)
- 2025-05-21Nature-affiliated publication used Tapestri to track precancerous clones
- 2024-01-04Brian Kim appointed CEO
- 2023-05-31Launched Tapestri v3 software update
- 2020-08-13Closed $70M Series C led by Novo Growth
- 2018-12-13Closed $30M Series B financing
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Mission Bio 2026 Company Profile: Valuation, Funding & Investors
- Products, Competitors, Financials, Employees, Headquarters Locations (2025-12-03)
- Mission Bio Closes $70 Million Series C Led by Novo Growth (2020-08-13)
- Mission Bio Raises $30M... (2018-12-13)
- Mission Bio Stock Price, Funding, Valuation, Revenue & Financial Statements (2025-08-04)
- Mission Bio Secures Equity Financing to Accelerate Single-Cell Tri-omics Platform Expansion (2025-08-05)
- Mission Bio Company Profile (2022-05-04)
- Revenue, Competitors, Alternatives (2022-04-16)
- Mission Bio
- Tapestri Single-cell Sequencing Platform
- Mission Bio Appoints Industry Veteran Brian Kim as CEO (2024-01-04)
- Mission Bio Appoints Dr. Zivjena Vucetic as CMO (2025-10-09)